How drugs get listed on the PBS
From TGA approval to PBAC submission, cost-effectiveness review, PBAC recommendations, ministerial decision, and PBPA price negotiation — the full PBS listings pathway explained step by step, including managed entry agreements for high-cost medicines.
The PBAC: Australia's HTA body for medicines
The Pharmaceutical Benefits Advisory Committee (PBAC) is an independent expert committee established under the National Health Act 1953. It is responsible for recommending to the Minister for Health which medicines should be listed on the PBS, at what price (via advice to the PBPA), and under what conditions (restrictions, authority requirements).
The PBAC conducts health technology assessment (HTA) — evaluating the clinical and economic evidence for each new drug relative to current standard of care. Unlike some HTA bodies, the PBAC considers both clinical effectiveness and cost-effectiveness, and its framework explicitly acknowledges uncertainty — particularly in submissions based on single trials or immature survival data.
The PBAC meets three times per year (March, July, November). All PBAC meeting outcomes are published on the PBS website ↗.
The PBS listing pathway: 6 steps
TGA approval
The drug must first receive TGA registration for at least one indication. TGA approval establishes that the medicine is safe and effective — but does not guarantee PBS listing. Sponsors typically pursue TGA approval before submitting to PBAC, though concurrent applications are possible.
PBAC submission
The sponsor submits a detailed economic dossier to the PBAC. The submission must include: clinical evidence (systematic review of trials vs comparator), economic model (cost-effectiveness analysis — incremental cost per QALY gained), budget impact analysis, and patient support data. Submissions are made up to 6 months before the scheduled PBAC meeting (March, July, November).
ESC and DUSC review
The Economics Sub-Committee (ESC) evaluates the economic model for validity and assumptions. The Drug Utilisation Sub-Committee (DUSC) estimates the population likely to use the medicine and the budget impact. Both provide advice to the full PBAC before the committee meeting.
PBAC meeting and recommendation
The PBAC meets three times per year. It reviews the submission and sub-committee advice, and may accept or reject submissions or request major or minor resubmissions. The PBAC recommends for listing if the medicine demonstrates clinically meaningful benefit at an acceptable cost relative to alternatives. The PBAC's recommendation is not binding on the Minister — it is advice.
Minister's decision and PBPA price negotiation
Following a positive PBAC recommendation, the Minister for Health decides whether to list the drug on the PBS. In practice, most positive PBAC recommendations proceed to listing. The Pharmaceutical Benefits Pricing Authority (PBPA) then negotiates the PBS listing price with the manufacturer, aiming to achieve a cost-effectiveness ratio acceptable to government.
PBS Schedule listing
The drug is listed on the PBS Schedule (published monthly at pbs.gov.au) with a specific benefit type, restriction criteria, maximum quantity, repeats, and listing price. Prescribers and pharmacists can dispense from the listing date.
What the PBAC evaluates
Head-to-head RCTs vs main comparator (existing standard of care). If no direct evidence, indirect comparisons are used. GRADE-style evidence quality assessment. Key outcomes: OS, PFS, QoL, event rates.
Incremental cost-effectiveness ratio (ICER) = (cost of new drug − cost of comparator) ÷ (QALYs gained with new drug − QALYs with comparator). Sensitivity analyses for uncertainty. No fixed threshold — contextual judgement.
Estimated number of PBS-eligible patients × expected uptake × net PBS cost. The DUSC independently models utilisation. High budget impact relative to expected benefit increases scrutiny.
Consumer organisations and clinical specialists may submit letters to the PBAC on disease burden, unmet need, and patient perspectives. These are weighed alongside the economic evidence, particularly for severe conditions.